Publications by authors named "S Rattotti"
Article Synopsis
- This study looked at treating early-stage follicular lymphoma with radiation therapy and a medicine called ofatumumab.
- They treated patients first with radiation and then gave ofatumumab to those still having cancer traces in their blood.
- Out of the 110 people in the study, many improved after treatment, with some showing no signs of the disease for a long time.
Article Synopsis
- - Marginal zone lymphomas (MZL) are a group of related subtypes that currently lack a standardized prognostic score for patients requiring systemic therapy.
- - Researchers developed a prognostic model based on a study of 501 patients, identifying five important factors that significantly affect progression-free survival (PFS) and creating three risk categories: low, intermediate, and high.
- - The newly proposed MZL International Prognostic Index (MZL-IPI) has been validated in multiple patient cohorts, showing reliable predictive value for both PFS and overall survival (OS) among MZL patients undergoing treatment.
Article Synopsis
- * Out of 12 enrolled patients, 10 responded well while 2 did not; 58.3% experienced adverse reactions, highlighting the complexities in treatment response and side effects.
- * While the overall diversity of GM did not significantly differ between groups, there were notable differences in specific bacterial taxa, suggesting that further research is needed to explore these relationships.
Early therapies to prevent severe COVID-19 have an unclear impact on patients with hematological malignancies. The aim of this study was to assess their efficacy in this group of high-risk patients with COVID-19 in preventing hospitalizations and reducing the SARS-CoV-2 shedding. This was a single-center, retrospective, observational study conducted in the Fondazione IRCSS Policlinico San Matteo of Pavia, Northern Italy.
View Article and Find Full Text PDFPurpose: We prospectively treated patients with hepatitis C virus (HCV)-associated indolent lymphomas with genotype-appropriate direct-acting antivirals (DAAs) with the aim to evaluate virologic and hematologic outcomes. No prospective studies in this setting have been published so far.
Methods: FIL_BArT is a prospective, multicenter, phase II trial that evaluated genotype-appropriate DAAs in untreated HCV-positive patients with indolent lymphomas without criteria for immediate conventional antilymphoma treatment.